Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$83.14 - $145.99 $4.36 Million - $7.66 Million
-52,500 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$110.08 - $142.92 $930,616 - $1.21 Million
-8,454 Reduced 13.87%
52,500 $6.23 Million
Q3 2021

Nov 15, 2021

BUY
$98.85 - $138.91 $1,977 - $2,778
20 Added 0.03%
60,954 $8.47 Million
Q4 2019

Feb 14, 2020

BUY
$40.86 - $57.65 $418,120 - $589,932
10,233 Added 20.18%
60,934 $3.32 Million
Q3 2019

Nov 14, 2019

SELL
$37.38 - $49.47 $5.4 Million - $7.15 Million
-144,545 Reduced 74.03%
50,701 $2.12 Million
Q2 2019

Aug 14, 2019

BUY
$39.79 - $67.01 $7.77 Million - $13.1 Million
195,246 New
195,246 $0

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $2.59B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Alyeska Investment Group, L.P. Portfolio

Follow Alyeska Investment Group, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.